Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly.See plans and pricing.See plans →
Typewriter raises $56M for jumping-gene technology and in vivo CAR-T development.
PRIVATESep 02, 2026•6 days ago
Amount Raised
$56 Million
Round Type
Venture - Series Unknown
Biotechnology
Description
Typewriter has secured $56 million in funding to advance its jumping-gene technology platform. The capital will support the development of in vivo CAR-T therapies using transposable elements to deliver full genes into human cells. This funding enables the company to progress its genetic engineering approach for treating diseases.
Company Information
Company
Typewriter
About
Typewriter is a biotechnology company developing jumping-gene technology for in vivo CAR-T cell therapy. The company focuses on using transposable genetic elements to deliver full genes into human cells for therapeutic purposes.
Don't miss Typewriter's next move
Get an email the moment Typewriter raises, hires an exec, or expands, usually minutes after it happens.